{"protocolSection":{"identificationModule":{"nctId":"NCT04273516","orgStudyIdInfo":{"id":"3498"},"organization":{"fullName":"Mazandaran University of Medical Sciences","class":"OTHER"},"briefTitle":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","officialTitle":"Aspirin Plus Rivaroxaban Efficacy and Safety in Embolic Stroke of Undetermined Source: A Randomized, Placebo Controlled, Outcome Assessor Blind, Feasibility Study","acronym":"AREST-ESUS"},"statusModule":{"statusVerifiedDate":"2023-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-08-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-10","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-30","type":"ACTUAL"},"studyFirstSubmitDate":"2020-02-15","studyFirstSubmitQcDate":"2020-02-15","studyFirstPostDateStruct":{"date":"2020-02-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-18","lastUpdatePostDateStruct":{"date":"2023-10-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Athena Sharifi Razavi","investigatorTitle":"Assistant Professor in Neurology","investigatorAffiliation":"Mazandaran University of Medical Sciences"},"leadSponsor":{"name":"Mazandaran University of Medical Sciences","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year.\n\nDespite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA","detailedDescription":"This is an outcome assessor blind, randomized, parallel, placebo-controlled pilot study on ischemic stroke of undetermined source which will be conducted in Bu Ali Sina hospital in Sari, Iran.\n\nPatients with recent stroke with criteria of ESUS, will be randomized to Rivaroxaban 2.5 mg BID plus ASA 80 mg daily or ASA 80 mg plus placebo (1:1 ratio) and have visit every 3 month until 1 year"},"conditionsModule":{"conditions":["Stroke","Prevention"],"keywords":["ESUS","DOACS","Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":42,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention","type":"EXPERIMENTAL","description":"Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily","interventionNames":["Drug: Rivaroxaban 2.5 Mg Oral Tablet"]},{"label":"Comparator","type":"PLACEBO_COMPARATOR","description":"Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily","interventionNames":["Drug: Rivaroxaban placebo tablets"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban 2.5 Mg Oral Tablet","description":"Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily","armGroupLabels":["Intervention"],"otherNames":["Axabin 2.5"]},{"type":"DRUG","name":"Rivaroxaban placebo tablets","description":"Placebo tablets add to ASA 80 mg daily that is standard treatment","armGroupLabels":["Comparator"],"otherNames":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Rate of stroke recurrence","description":"Number of stroke events during 1 year of study","timeFrame":"Rate of stroke recurrence during one year fallow up"},{"measure":"Rate of major bleeding","description":"Rate of major bleeding according to criteria of the International Society of Thrombosis and Hemostasis","timeFrame":"During 1 year of study"}],"secondaryOutcomes":[{"measure":"Rate of stroke or systemic embolisms","description":"Number of stroke or systemic embolisms recurrence during 1 year of study","timeFrame":"During 1 year of study"},{"measure":"Mortality rate","description":"Number of all cause mortality during study","timeFrame":"During 1year of study"},{"measure":"Rate of non-major bleeding","description":"Rate of non-major bleeding according to criteria of the International Society of Thrombosis and Hemostasis","timeFrame":"During 1year of study"},{"measure":"Rate of intracranial bleeding","description":"Rate of ICH during study","timeFrame":"During 1year of study"},{"measure":"Rate of fatal bleeding","description":"Rate of fatal bleeding in any site","timeFrame":"During 1 year of study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. signing the inform consent\n2. recent ischemic stroke ( 7-60) days with criteria of ESUS\n3. only one risk factors of potential embolic source including:\n\n   1. PTFV1 in standard ECG ≥0.05 mm.s or ≥0.005 mv.s\n   2. LVH in standard ECG( Sokolow index≥ 35 mm) or on echocardiography\n   3. Moderate or severe valvular disorder on echocardiography (except MS)\n   4. PFO without indication of occlusion\n   5. Left atrium enlargement in echocardiography\n\nExclusion Criteria:\n\n1. History of hypersensitivity to the investigational medicinal product\n2. Indication for anticoagulation\n3. Indication for dual antiplatelet therapy\n4. Contraindication to investigational medications\n5. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding\n6. Gastrointestinal bleed or major surgery within 3 months\n7. Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months\n8. HAS-BLED score \\>3\n9. Severe non-cardiovascular comorbidity with life expectancy \\< 3 months\n10. Severe renal failure, defined as Glomerular Filtration Rate (GFR) \\<15ml/min, Dialysis, transplant, Cr \\>2.26 mg/dL\n11. Severe hepatic insufficiency, Cirrhosis or Bilirubin \\>2x Normal or AST/ALT/AP \\>3x Normal\n12. Modified Rankin Scale of \\>=4 at time of randomization or inability to swallow medications.\n13. Hemorrhagic transformation of infarction detected by Brain CT or MRI at the time of drug application\n14. Radiological or microbiological evidence of COVID-19 infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Athena Sharifi-Razvi","affiliation":"mazandaran university of medical science","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Monireh Ghazaeian","affiliation":"mazandaran university of medical science","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Bou- Ali Sina Hospital","city":"Sari","state":"Mazandaran","country":"Iran, Islamic Republic of","geoPoint":{"lat":36.56332,"lon":53.06009}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"accessCriteria":"Data will be available for researchers and scientific persons after request and review the proposal ."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083262","term":"Embolic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000083242","term":"Ischemic Stroke"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M2403","name":"Embolic Stroke","asFound":"Embolic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}